secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-08-12T13:30:54+00:00
Accession:  0001437749-26-027165
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q2 net loss $5.3M; initiates rolling NDA for ALXN1840
-------------------------------------------------------------

- Net loss $5.3M ($0.62/share) vs $2.5M ($0.35) in Q2 2025; R&D spend $4.77M (up from $1.73M).
- Cash and investments $134.3M as of June 30, 2026; runway through at least Dec 31, 2027.
- Rolling NDA submission to FDA for ALXN1840 initiated July 22, 2026; RPD designation granted June 30, 2026.
- RPD designation supports potential pediatric Priority Review Voucher at NDA approval; commercial team added.
- Positive Phase 3 FoCus data presented at EAN 2026 and AAN 2026 showing neurologic benefit vs standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/0001437749-26-027165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/mnpr20260811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer